Bicara Therapeutics BCAX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's additional paid-in capital?
- Bicara Therapeutics (BCAX) reported additional paid-in capital of $929.37M in Q1 2026.
- How has Bicara Therapeutics's additional paid-in capital changed year-over-year?
- Bicara Therapeutics's additional paid-in capital increased by 29.7% year-over-year, from $716.81M to $929.37M.
- What is the long-term trend for Bicara Therapeutics's additional paid-in capital?
- Over 2 years (2023 to 2025), Bicara Therapeutics's additional paid-in capital has grown at a 1237.4% compound annual growth rate (CAGR), from $4.25M to $760.17M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.